Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.

Key facts

Study ID

NCT01228513

Run by

Bayer

People needed

263

Starts

2010-11-01

Expected to finish

2012-04-01

Last updated by the study team

2016-01-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
• Body surface area affected by atopic dermatitis at or less than 15% at start of treatment

You may not qualify if…

• Pregnancy and breast-feeding
• Conditions that may pose a threat to the patient or effect the outcome of the study
• Wide-spread atopic dermatitis (AD) requiring systemic treatment
• Immuno-compromized conditions
• At least 2 weeks after local AD treatment and treatment with systemic antibiotics
• At least 1 month after systemic AD treatment

Where it is running

• Study site — Anaheim, California, United States
• Study site — Honolulu, Hawaii, United States
• Study site — Boise, Idaho, United States
• Study site — Chicago, Illinois, United States
• Study site — Boston, Massachusetts, United States
• Study site — Warren, Michigan, United States
• Study site — Fridley, Minnesota, United States
• Study site — New York, New York, United States
• Study site — Portland, Oregon, United States
• Study site — Austin, Texas, United States
• Study site — College Station, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Webster, Texas, United States
• Study site — Kawaguchi Saitama, Japan
• Study site — Tokyo, Japan
• Study site — Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.